What: Shares of Array BioPharma, a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from ...

NEW YORK (AP) — Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Array BioPharma Inc. of Boulder, Colo., and Celgene Corporation, a Summit-based biopharmaceutical company, have announced a research and development collaboration on the discovery, development and ...

What: Shares of Array BioPharma, a biopharmaceutical company that's focused on developing novel drugs to fight cancer, skyrocketed by 51% in January, based on data from S&P Capital IQ, after ...

Boulder’s Array BioPharma Inc. is merging with Pfizer Inc. in an $11.4 billion deal. The merger agreement was announced Monday. Array BioPharma is a commercial stage biopharmaceutical company focused ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

After reporting fiscal second-quarter financials that were better than hoped, Array BioPharma (NASDAQ: ARRY) saw its shares surge 11.3% as of 3:40 p.m. EST on Tuesday. Array BioPharma has said in the ...

In response to the company posting good-looking fiscal 2019 first-quarter results, shares of Array BioPharma (NASDAQ: ARRY) , a commercial-stage biopharma focused on cancer, rose as much as 10% in ...

—Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term —Opportunity to strengthen category ...

Array BioPharma has said in the past that it thinks its Mektovi and Braftovi cancer drugs target indications that could be worth $1 billion. And while sales remain a long way from the billion-dollar ...